Sonographic measurement of the thickness of subcutaneous tissues in nonalcoholic fatty liver disease versus other chronic liver diseases

PURPOSE: To measure an average subcutaneous tissue thickness in nonalcoholic fatty liver disease (NAFLD) and other liver diseases using bedside sonography and make comparisons of thickness between groups. The study also addressed whether a cut-off subcutaneous tissue thickness exists below which NAFLD is unlikely. METHODS: Sonograph was performed on 113 consecutive patients with chronic liver disease. Diagnosis was derived from serological data combined with liver biopsy in all cases. Distance was measured between the skin and the liver surface and was labeled the subcutaneous tissue thickness. RESULTS: Of the 113 patients, 16 were diagnosed with NAFLD, 56 were diagnosed with chronic hepatitis C, 17 were diagnosed with autoimmune liver disease, and 24 had miscellaneous diagnoses (hepatitis B, hemochromatosis, granulomatous hepatitis, and cryptogenic hepatitis). The subcutaneous tissue thickness was 25.6 mm +/- 5.6 mm in NAFLD versus 19.5 mm +/- 5.2 in the non-NAFLD patients (p < 0.001). The subcutaneous tissue thickness of the HCV group was 20.2 mm +/- 4.8, and although it was not different than all other patients, it was different from the NAFLD patients (p < 0.01). Fifteen out of sixteen of the NAFLD patients had a greater than average subcutaneous tissue thickness (20 mm). CONCLUSIONS: A sonographically measured subcutaneous tissue thickness of less than 20 mm makes the diagnosis of NAFLD unlikely.     

2型糖尿病患者非酒精性脂肪性肝病与代谢及颈动脉内膜中层厚度的相关性研究

目的 探讨2型糖尿病(T2DM)患者非酒精性脂肪性肝病(NAFLD)与代谢指标及颈动脉内膜中层厚度(CIMT)的相关性.方法 根据肝脏B超结果,将321例T2DM患者分为合并NAFLD组和单纯T2DM组,比较2组患者的体重指数(BMI)、血压、血糖、血脂、尿酸、胰岛素、C肽、胰岛素抵抗指数(HOMA-IR)等代谢指标,并分析丙氨酸氨基转移酶(ALT)与上述指标的关系;比较合并NAFLD组与单纯T2DM组的CIMT,并通过相关及回归等方法探讨NAFLD及ALT与CIMT之间的相关性.结果 (1)合并NAFLD组BMI、甘油三酯(TG)、尿酸、空腹血糖(FBG)、空腹胰岛素(FIns)、空腹C肽(FCP)、HOMA-IR较单纯T2DM组显著升高,而高密度脂蛋白胆固醇(HDL-C)明显降低,其中BMI(OR=1.25,P＜0.001)、TG(OR=1.74,P=0.008)、HOMA-IR(OR=2.33,P=0.010)是NAFLD的独立危险因素,HDL-C(OR=0.04,P＜0.001)是其保护因素;(2)ALT与BMI(r=0.255,P＜0.001)、TG(r=0.156,P＜0.018)、尿酸(r=0.239,P＜0.001)、FIns(r=0.213,P=0.001)、FCP(r=0.199,P＜0.003)、HOMA-IR(r=0.247,P＜0.001)呈正相关,与HDL-C(r=-0.199,P=0.002)呈负相关,其中BMI(β=0.456,P=0.048)、尿酸(β=0.021,P=0.025)及HOMA-IR(β=3.634,P=0.004)是独立相关因素;(3)合并NAFLD组与单纯T2DM组之间的CIMT差异无统计学意义,而多元回归分析表明ALT与CIMT独立相关(β=0.002,P=0.013).结论 T2DM合并NAFLD患者存在更严重的代谢紊乱及胰岛素抵抗,ALT是T2DM患者颈动脉内膜中层增厚的独立危险因素.

Abstract：

Objective To investigate the association between nonalcoholic fatty liver disease (NAFLD) and metabolism or carotid intima-media thickness (CIMT) in Type 2 diabetic(T2DM). Methods According to the liver B-ultrasonography, a total of 321 T2DM patients were divided into two groups, with or without NAFLD. Metabolic indexes such as BMI, BP, blood glucose, blood lipid, uric acid ( UA ), insulin, C-peptipe,insulin resistance index(HOMA-IR) between the two groups were compared, and the relationships between alanine aminotransferase (ALT) and the above indexes were analyzed. Furthermore,the CIMT of the two groups were compared, and the relationships between NAFLD, ALT and CIMT were investigated by correlation and regression analysis. Results Compared with the group without NAFLD, the patients with NAFLD had higher level of BMI, triglyceride ( TG ), UA, fasting blood glucose ( FBG ), fasting insulin ( FIns ), fasting C peptide (FCP) ,HOMA-IR,and lower level of high density lipoprotein ( HDL-C ) significantly; BMI ( OR = 1.25, P ＜0. 001 ), TG ( OR = 1.74, P = 0. 008 ) and HOMA-IR ( OR = 2. 33, P = 0.010) were independent risk factors of NAFLD while H DL-C was independent protective factor; ALT was positively correlated with BMI (r = 0. 255, P ＜0. 001 ) ,TG(r =0. 156,P ＜0. 018) ,UA(r =0. 239,P ＜0. 001 ) ,FIns(r =0. 213,P =0. 001) ,FCP(r =0. 199,P ＜0. 003), HOMA-IR ( r = 0. 247, P ＜ 0. 001 ) and negatively correlated with HDL-C ( r = - 0. 199, P =0. 002) ,and BMI (β =0. 456,P =0. 048) ,UA (β =0. 021 ,P =0. 025) and HOMA-IR(β =3.634 ,P =0. 004)were independent associated facrors. The difference of CIMT between the two groups didn't reach statistical significance, while mutiple regression analysis revealed that ALT was independently associated with CIMT(β =0. 002,P = 0. 013). Conclusion T2DM patients with NAFLD show more serious disorder of metabolism and insulin resistance. ALT is an independent risk factor of CIMT in T2DM patients.     

超声测量肾周及肾旁脂肪厚度在评估非酒精性脂肪肝患者肝脂肪浸润程度中的意义

目的 探讨腹部超声测量肾周及肾旁脂肪厚度（UFT）在定量评估非酒精性脂肪肝（NAFLD）患者肝脂肪浸润程度中的意义。方法 应用彩色多普勒超声测量90例NAFLD患者肾周及肾旁脂肪厚度（UFT）、腰围及体质量指数（BMI）。根据肝脂肪浸润程度将NAFLD患者分为轻度、中度和重度脂肪肝组。结果 轻度、中度和重度NAFLD患者肾周及肾旁UFT比较,差异有统计学意义（P〈0．05）。NAFLD患者。肾周及肾旁UFT和肝脂肪浸润程度比较,呈显著正相关（r=0．89,P〈0．01）。NAFLD患者肾周及肾旁UFT和腰围比较,呈显著正相关（r=0．81,P〈0．01）。NAFLD患者肾周及肾旁UFT和BMI比较,呈显著正相关（r=0．79,P〈0．01）。结论 超声测量肾周及肾旁UFT在预测NAFLD患者脂肪肝的发病和发展中有重要的临床应用价值,可准确地评估NAFLD患者肝脂肪浸润程度。     

Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients

OBJECTIVE—Adipocyte fatty acid–binding protein (A-FABP) is a major cytoplasmic protein in adipocytes and macrophages and is closely associated with metabolic syndrome, type 2 diabetes, and atherosclerosis. Here, we investigated whether A-FABP was associated with nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes.RESEARCH DESIGN AND METHODS—We enrolled 181 type 2 diabetic patients. Clinical and biochemical metabolic parameters were measured. The severity of NAFLD was measured by ultrasound. A-FABP, adiponectin, and retinol-binding protein-4 (RBP-4) were determined by enzyme-linked immunosorbent assay.RESULTS—A-FABP levels, defined as more than a moderate degree of fatty liver compared with men, those without metabolic syndrome, and those without NAFLD, were higher in women, patients with metabolic syndrome, and patients with overt NAFLD, respectively. Adiponectin was decreased according to the severity of NAFLD, but RBP-4 showed no difference. Age- and sex-adjusted A-FABP showed positive correlations with BMI, waist-to-hip ratio, waist circumference, triglycerides, γ-glutamyltransferase, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), A1C, and C-reactive protein (CRP) but showed negative correlation with HDL cholesterol. The odds ratio (OR) for the risk of overt NAFLD with increasing levels of sex-specific A-FABP was significantly increased (OR 2.90 [95% CI 1.15–7.29] vs. 7.87 [3.20–19.38]). The OR in the highest tertile of A-FABP remained significant after adjustments for BMI, waist circumference, A1C, HDL cholesterol, triglycerides, HOMA-IR, CRP, and hepatic enzymes.CONCLUSIONS—Our study demonstrates that serum A-FABP is significantly associated with NAFLD in type 2 diabetes, independent of BMI, waist circumference, HOMA-IR, A1C, triglycerides, HDL cholesterol, and CRP.Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic elevation of hepatic enzymes in the general population without known liver disease. NAFLD is observed in 20–30% of the total population (1) and in 75% of type 2 diabetic patients (2,3) in developed countries. NAFLD is characterized by hepatic insulin resistance. In epidemiologic studies, NAFLD has been reported to be closely associated with obesity, dyslipidemia, and diabetes (4–6). In prospective studies, NAFLD was a risk factor for type 2 diabetes and cardiovascular disease independent of the classic risk factors (7,8). Hence, NAFLD is considered a hepatic manifestation of metabolic syndrome.Adipocyte fatty acid–binding protein (A-FABP; also known as FABP-4 or aP2) is a major cytoplasmic protein and is involved in the regulation of lipid metabolism. A-FABP is expressed abundantly in mature adipocytes and activated macrophages. A-FABP binds fatty acid ligands with high affinity and functions in intracellular fatty acid trafficking, regulation of lipid metabolism, and modulation of gene expression (9,10). In obese mice lacking A-FABP, dyslipidemia and peripheral insulin resistance are improved and β-cell function is preserved (11). Boord et al. (12) reported that combined adipocyte-macrophage fatty acid–binding protein deficiency improves glucose and lipid metabolism, reduces atherosclerosis, and improves survival in apoE^-/- mice. In cross-sectional studies, A-FABP was closely associated with obesity and metabolic syndrome (13,14). In prospective studies, A-FABP levels predicted the development of metabolic syndrome and type 2 diabetes (15,16). Furthermore, Yeung et al. (17) reported that A-FABP levels were independently associated with carotid atherosclerosis. Tuncman et al. (18) reported that individuals with an aP2 variant had lower triglycerides and a reduced risk of coronary heart disease and obesity-induced type 2 diabetes. These findings suggested that A-FABP is closely associated with insulin resistance and plays a central role in the development of metabolic syndrome, type 2 diabetes, and atherosclerosis. Maeda et al. (19) demonstrated protection against fatty liver disease in mice lacking aP2 and mal1 on high-fat diet. However, a relationship between A-FABP and NAFLD, a hepatic manifestation of metabolic syndrome, has not yet been established in a human study.We hypothesized that patients with NAFLD might have higher A-FABP levels and that A-FABP might show a positive correlation with the severity of NAFLD on ultrasound. To test this hypothesis, we investigated the relationship between serum A-FABP levels and NAFLD in type 2 diabetic patients.     

肝脂汤配合饮食护理对非酒精性脂肪肝患者的影响

目的探讨肝脂汤配合饮食护理对非酒精性脂肪肝患者的影响。方法选取2013年1—12月收治于上海中医药大学附属普陀医院的非酒精性脂肪肝患者60例,随机分为肝脂汤组和肝脂汤配合饮食护理组各30例,观察两组患者1个疗程后血脂指标、肝功能指标、体质指数(BMI)、B超影像及患者不适主症情况。结果服用肝脂汤后两组患者的血脂指标、肝功能指标、BMI、B超影像及患者不适主症等均有改善,但观察组改善更为明显,两组比较差异有统计学意义(P0.05)。结论肝脂汤配合饮食护理可提高非酒精性脂肪肝患者的治疗效果,有利于促进患者康复,提高患者的生活质量。     

Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease

OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) is closely associated with several metabolic syndrome features. We assessed whether NAFLD is associated with carotid artery intima-media thickness (IMT) as a marker of subclinical atherosclerosis and whether such an association is independent of classical risk factors, insulin resistance, and metabolic syndrome features. RESEARCH DESIGN AND METHODS: We compared carotid IMT, as assessed by ultrasonography, in 85 consecutive patients with biopsy-proven NAFLD and 160 age-, sex-, and BMI-matched healthy control subjects. RESULTS: NAFLD patients had a markedly greater carotid IMT (1.14 +/- 0.20 vs. 0.82 +/- 0.12 mm; P < 0.001) than control subjects. The metabolic syndrome (according to Adult Treatment Panel III criteria) and its individual components were more frequent in those with NAFLD (P < 0.001). The marked differences in carotid IMT observed between the groups were only slightly weakened after adjustment for age, sex, BMI, smoking history, LDL cholesterol, insulin resistance (by homeostasis model assessment), and metabolic syndrome components. Notably, carotid IMT was strongly associated with degree of hepatic steatosis, necroinflammation, and fibrosis among NAFLD patients (P < 0.001 for all). Similarly, by logistic regression analysis, the severity of histological features of NAFLD independently predicted carotid IMT (P < 0.001) after adjustment for all potential confounders. CONCLUSIONS: These results suggest that the severity of liver histopathology among NAFLD patients is strongly associated with early carotid atherosclerosis, independent of classical risk factors, insulin resistance, and the presence of metabolic syndrome.     

西格列汀联合二甲双胍对2型糖尿病合并非酒精性脂肪肝患者的疗效观察

目的:探讨西格列汀与格列吡嗪治疗2型糖尿病合并非酒精性脂肪肝患者的疗效,分析2种药物对患者血糖及肝功能的影响。方法:选取2015年6月至2017年4月上海市第三康复医院收治的112例2型糖尿病合并非酒精性脂肪肝患者,采用数字表法随机分为西格列汀组和格列吡嗪组,各56例。西格列汀组患者给予二甲双胍联合西格列汀治疗,格列吡嗪组患者给予二甲双胍联合格列吡嗪治疗。对比两组患者的脂肪肝疗效,并比较两组患者治疗前后的血糖、肝功能、血脂及胰岛素抵抗指数(HOMA-IR)等指标。结果:西格列汀组患者的总有效率为94.6%(53/56),高于格列吡嗪组(75.0%,42/56;P0.05)。两组患者的血糖、血脂指标较治疗前均显著改善,但两组间差异无统计学意义;两组患者的肝功能(AST、ALT、GGT)及HOMA-IR较治疗前显著改善,西格列汀组改善程度显著优于格列吡嗪组,差异有统计学意义(P0.05)。西格列汀组总体不良反应发生率为19.6%(11/56),格列吡嗪组总体不良反应发生率为17.9%(10/56),两组差异无统计学意义。结论:西格列汀联合二甲双胍治疗2型糖尿病合并非酒精性脂肪肝能够提高脂肪肝的治疗效果,与格列吡嗪相比能够更有效地改善患者的肝功能及HOMA-IR,值得临床推广。     

磁共振技术在非酒精性脂肪肝病中准确定量脂肪含量的应用

非酒精性脂肪肝病近年来增长迅速且呈低龄化发展趋势,虽然它为良性病变但可以影响到其他慢性肝病的进展,任其发展可能最终导致肝脏的衰竭。利用MR成像技术定量分析是目前研究的热点,~1H-MRS和m Dixon技术作为无创性方法定量诊断脂肪肝,可以帮助临床医生及时治疗已经发生脂肪变性的肝细胞使其得以恢复正常。本文就1H-MRS和m Dixon技术定量评价非酒精性脂肪肝患者肝脏脂肪含量的应用作一综述。     

Serum galectin-3 levels in patients with nonalcoholic fatty liver disease

Objectives

Galectin-3 might serve as a biomarker of human metabolic alterations. We measured serum levels of galectin-3 in patients with nonalcoholic fatty liver disease (NAFLD) and examined their association with clinical and histological phenotypes.

Design and methods

Serum levels of galectin-3 were assayed in 71 patients with biopsy-proven NAFLD and 39 controls.

Results

Serum galectin-3 levels did not differ in patients with NAFLD (median 4.1 ng/mL; interquartile range: 1.5–5.5 ng/mL) compared with healthy controls (median 3.1 ng/mL; interquartile range: 0.8–7.5 ng/mL, P = 0.93). Among patients with NAFLD, however, serum galectin-3 levels correlated significantly with BMI (r = 0.267, P < 0.05). This association persisted after adjustment for potential confounders (β = 0.30; t = 2.11, P < 0.05).

Conclusions

Although galectin-3 was modestly associated with BMI, our results do not support the hypothesis that levels of this molecule are altered in patients with NAFLD.     

血清铁蛋白对非酒精性脂肪肝患者早期肝纤维化的诊断价值

目的研究血清铁蛋白(SF)对非酒精性脂肪肝(NAFLD)患者早期肝纤维化的诊断价值。方法随机选取104例NAFLD患者和60例健康人进行血清学、肝脏B超和SF检查。NAFLD患者行肝脏活组织检查。分析并评价SF对NAFLD患者早期肝纤维化的诊断价值。结果 NAFLD患者的丙氨酸氨基转移酶(ALT)、γ-谷氨酰转移酶(GGT)、总胆固醇(TC)、三酰甘油(TG)、透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原氨基端肽(PⅢNP)、Ⅳ型胶原(CⅣ)、SF均高于健康对照组,差异有统计学意义(P0.05)。0期肝纤维化患者的HA、CⅣ和SF小于早期患者,差异有统计学意义(P0.05)。在早期患者中,相关性分析显示SF水平与HA、CⅣ呈正相关(rHA=0.44,rCⅣ=0.53,P0.05)。ROC曲线发现SF对早期肝纤维化患者的诊断曲线下面积为0.688(P=0.005),当SF为93μg/L时,诊断的灵敏度为73%,特异性为67%。结论血清SF的升高能够反映NAFLD患者早期肝纤维化的变化,有望成为NAFLD早期肝纤维化的血清学辅助诊断指标。     

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.     

Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model

This study aimed to evaluate the relationship between gut probiotic flora and nonalcoholic fatty liver disease in a diet-induced rat model, and to compare the effects of two different probiotic strains on nonalcoholic fatty liver disease. Forty male Sprague-Dawley rats were randomized into 4 groups for 12 weeks: control (standard rat chow), model (fat-rich diet), Lactobacillus (fat-rich diet plus Lactobacillus acidophilus), and Bifidobacterium (fat-rich diet plus Bifidobacterium longum) groups. Probiotics were provided to rats in drinking water (10¹⁰/ml). Gut bifidobacteria and lactobacilli were obviously lower at weeks 8 and 10, respectively, in the model group compared with the control group. Supplementation with Bifidobacterium significantly attenuated hepatic fat accumulation (0.10 ± 0.03 g/g liver tissue) compared with the model group (0.16 ± 0.03 g/g liver tissue). However, there was no improvement in intestinal permeability in either the Lactobacillus or the Bifidobacterium group compared with the model group. In all 40 rats, the hepatic total lipid content was negatively correlated with gut Lactobacillus (r = −0.623, p = 0.004) and Bifidobacterium (r = −0.591, p = 0.008). Oral supplementation with probiotics attenuates hepatic fat accumulation. Further, Bifidobacterium longum is superior in terms of attenuating liver fat accumulation than is Lactobacillus acidophilus.     

非酒精性脂肪肝患者体内铁代谢水平临床分析

目的研究铁代谢相关指标在非酒精性脂肪肝(NAFLD)患者中的水平及其意义。方法选取127例NAFLD患者和130例健康人进行血清学、肝脏B超和铁代谢指标检查。NAFLD患者行肝脏活组织检查。分析并评价血清铁(SI)代谢指标在NAFLD患者的变化。结果 NAFLD患者体质量指数、腰围、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转移酶(GGT)、总胆固醇(TC)和三酰甘油(TG)明显高于健康者,差异有统计学意义(P0.05)。NAFLD患者铁代谢的相关指标SI、铁蛋白(SF)高于健康者,差异有统计学意义(P0.05);铁调素(HEPC)低于健康者,差异有统计学意义(P0.05)。女性NAFLD患者血清SI和SF水平均低于男性NAFLD患者,差异有统计学意义(P0.05),肥胖NAFLD患者血清SI和SF均高于体质量正常的NAFLD患者,差异有统计学意义(P0.05),HEPC相对较低(P0.05)。相关性分析结果显示,SI与ALT、TG、TC呈正相关(P0.05),SF与ALT、TC呈正相关(P0.05),HEPC与ALT、GGT、TG、TC均呈负相关(P0.05)。结论血清SI、SF和HEPC水平与NAFLD患者的肥胖和肝功能相关,联合相关指标检测有助于判断NAFLD患者肝损伤的进展。     

非酒精性脂肪肝治疗进展

近年来随着生活水平的改善和生活方式的改变，非酒精性脂肪肝的发病率不断升高，其病因和发病机制尚未完全明了，针对脂肪肝的治疗尚缺乏有效的药物。本文就近年来对非酒精性脂肪肝的治疗进展作一综述。     

非酒精性脂肪肝肝纤维化评分与脂肪肝及胰岛素抵抗的相关性研究

目的分析非酒精性脂肪肝肝纤维化评分（NAFLDFS）与非酒精性脂肪肝（NAFLD）及胰岛素抵抗（瓜）的相关性。方法以来自江苏徐州地区的2622例健康体检人群为研究对象,检测受试者的血清谷丙转氨酶（“r）,谷草转氨酶（AsT）,血小板计数（PLT）,血清白蛋白（ALB）,空腹血糖（FBG）,餐后2h血糖（PBG）,空腹胰岛素（Fins）等相关生化指标,计算出NAFLDFS及胰岛素抵抗指数（HOMA2-IR）,将研究对象按非酒精性脂肪肝纤维化评分的低诊断阈值（～1．455）及高诊断阈值（0．676）分成三组,A1组：NAFLDFS〈-1．455;A2组：0．676≥NAFLDFS≥-1．455和A3组NAFLDFS〉0．676。Pearson分析肝纤维化评分与各指标相关性;运用二元Logistic回归计算NAFLDFS与NAFLD、IR的风险性。结果随着NAFLDFS值增高,年龄（Age）、体重（Weight）、体重指数（BMI）、腰围（wc）、臀围（Hip）、糖化血红蛋白（HbAlc）、颈围（NC）、FBG、PBG、Fins、收缩压（SBP）、舒张压（DBP）、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL-C）水平逐渐增高,且三组问的差异有统计学意义;而ALT、AST、PLT、ALB、高密度脂蛋白（HDL．c）随着NAFLDFS值的增高而减小。Pearson分析显示Age、NC、WC、Hip、Weight、BMI、HbAlc、FBG、PBG、PLT与NAFLDFS正相关。随着NAFLDFS值的增加,NAFLD与取的患病风险（OR）也增加。NAFLD的患病风险由1．22（OR=1．22）增加到1．79（OR=1．79）：IR的患病风险由1．13（OR=1．13）增加到1．91（OR=1．91）;进一步校正性别及年龄后,NAFLD的患病风险由1．15（OR=1．15）增加到1．53（OR=1．53）;IR的患病风险由1．15（OR=1．15）增加到2．02（OR=2．02）。结论NAFLDFS与NAFLDF及瓜密切相关,在临床上可将其作为简易评价NAFLD及IR的指标。